6 relationship between depressive symptoms and mirna expression level in monocytes of patients with depression before and after antidepressant treatment

7 Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: Cross-sectional analysis of baseline data from PERFORM-J.

8 Sex-specific plasma metabolome signatures in major depressive disorder.

9 The paradox of relaxation training: Relaxation induced anxiety and mediation effects of negative contrast sensitivity in generalized anxiety disorder and major depressive disorder.

10 Association of thyroid dysfunction with suicide attempts in first-episode and drug naïve patients with major depressive disorder.

11 A genome-wide association meta-analysis of prognostic outcomes following cognitive behavioural therapy in individuals with anxiety and depressive disorders

12 Depressive disorder and Austim Spectrum Disorder: Scoping review since DSM-5 publication

13 Ratio of plasma BDNF to leptin levels are associated with treatment response in major depressive disorder but not in panic disorder: A 12-week follow-up study.

14 An Online Mindfulness-Based Cognitive Behavioral Therapy Intervention for Youth Diagnosed With Major Depressive Disorders: Protocol for a Randomized Controlled Trial.

15 White matter disturbances in major depressive disorder: a coordinated analysis across 20 international cohorts in the ENIGMA MDD working group.

16 Comorbidity with more anxiety disorders associated with a poorer prognosis persisting at the 10-year follow-up among patients with major depressive disorder.

17 Prevalence and recognition of depressive disorders among Chinese older adults receiving primary care: A multi-center cross-sectional study.

18 Major depressive disorder in children and adolescents.

19 Abnormal functional connectivity strength in first-episode, drug-naïve adult patients with major depressive disorder.

20 Investigating executive control network and default mode network dysfunction in major depressive disorder.

21 Blame-rebalance fMRI neurofeedback in major depressive disorder: A randomised proof-of-concept trial.

22 Natural health products, dietary minerals and over-the-counter medications as add-on therapies to antidepressants in the treatment of major depressive disorder: a review.

23 Comparative efficacy and safety of L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials.

24 Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial.

25 Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial.

26 Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials

27 Art as a Therapeutic Tool in Depressive Disorders: a Systematic Review of the Literature.

28 Using text mining to extract depressive symptoms and to validate the diagnosis of major depressive disorder from electronic health records.

29 Altered dynamic functional connectivity in weakly-connected state in major depressive disorder.

30 Insulin sensitivity, proinflammatory markers and adiponectin in young males with different subtypes of depressive disorder.

31 Indices of insulin resistance and glucotoxicity are not associated with bipolar disorder or major depressive disorder, but are differently associated with inflammatory, oxidative and nitrosative biomarkers.

32 C-reactive protein: A differential biomarker for major depressive disorder and bipolar II disorder.

33 Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder

34 Cognition in older adults with bipolar disorder versus major depressive disorder

35 Novel markers of inflammation and their relevance to depression: The unique relation of the Neutrophil: Lymphocyte Ratio (NLR) and the Cortisol:C-reactive protein (CORT/CRP) ratio to an intermediate phenotype of Major Depressive Disorders (MDD)

36 An overview of the heterogeneity of major depressive disorder: Current knowledge and Future prospective.

37 The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model.

38 The Relationship Between Smoking and Suicidal Behavior in Psychiatric Patients with Major Depressive Disorder

39 Adverse childhood experiences and alexithymia in patients with major depressive disorder.

40 Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.

41 Double Blinded Randomized Trial of Subcutaneous Trigeminal Nerve Stimulation as Adjuvant Treatment for Major Unipolar Depressive Disorder

42 Quantifying the level of difficulty to treat major depressive disorder with antidepressants: Treatment Resistance to Antidepressants Evaluation Scale.

43 Overeating and food addiction in Major Depressive Disorder: Links to peripheral dopamine.

44 [A pilot study of transcranial alternating current stimulation in the treatment of drug-naive adult patients with major depressive disorder].

45 The Influence of Pharmacodynamic Genes on Fluoxetine Response in Pediatric Anxiety and Depressive Disorders.

46 Sex differences on the relation between major depressive disorder and labor market outcomes: A national prospective study.

47 Decreased plasma glial cell line-derived neurotrophic factor level in major depressive disorder is associated with age and clinical severity.

48 Impact of Cognitive Symptoms on Health-Related Quality of Life and Work Productivity in Chinese Patients with Major Depressive Disorder: Results from the PROACT Study.

49 Major Depressive Disorder Is Associated With Cardiovascular Risk Factors and Low Omega-3 Index

50 Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder

51 Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration

52 Major Depressive Disorder Predicts Completion, Adherence, and Outcomes in Cardiac Rehabilitation: A Prospective Cohort Study of 195 Patients With Coronary Artery Disease

53 Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity

54 Failure Rate and “Professional Subjects” in Clinical Trials of Major Depressive Disorder

55 Reply to Failure Rate and “Professional Subjects” in Clinical Trials of Major Depressive Disorder

56 Report by the ACNP Task Force on response and remission in major depressive disorder

57 Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review

58 Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder

59 Duloxetine, 60 mg Once Daily, for Major Depressive Disorder: A Randomized Double-Blind Placebo-Controlled Trial

60 genome-wide analysis in uk biobank identifies four loci associated with mood instability and genetic correlation with major depressive disorder, anxiety disorder and schizophrenia

61 psychosocial interventions in depressive disorders

62 features of cognitive dysfunction in patients with depressive disorder and cerebrovascular pathology

63 brain-derived neurotrophic factor and major depressive disorder: evidence from meta-analyses

64 cost-effectiveness of collaborative care including pst and an antidepressant treatment algorithm for the treatment of major depressive disorder in primary care; a randomised clinical trial

65 psychostimulants in the treatment of depressive disorders

66 features of pathomorphosis of endogenous depressive disorders

67 symptom severity, affective and somatic symptom clusters predict poorer social cognition performance in current but not remitted major depressive disorder

68 t cell phenotype and t cell receptor repertoire in patients with major depressive disorder

69 psychiatric manifestations of sporadic creutzfeldt-jakob disease simulate depressive disorder with psychotic symptoms

70 coexisting fibromyalgia, depressive disorder, and tension headache: chance finding or common pathology?

71 p300 latency as an indicator of severity in major depressive disorder

72 improvement in the approaches to the treatment of emigrants and re-emigrants with depressive disorders

73 does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction?

74 anti-n-methyl-d-aspartate receptor encephalitis causing a prolonged depressive disorder evolving to inflammatory brain disease

75 a review of the role of social cognition in major depressive disorder

76 major depressive disorder with melancholia displays robust alterations in resting state heart rate and its variability: implications for future morbidity and mortality

77 analysis of the association of mir124-1 and its target gene rgs4 polymorphisms with major depressive disorder and antidepressant response

78 changes of grey matter volume in first-episode drug-naive adult major depressive disorder patients with different age-onset

79 exercise leads to better clinical outcomes in those receiving medication plus cognitive behavioral therapy for major depressive disorder

80 c-quality: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional italian settings of veneto and sardinia

81 neural activity during interoceptive awareness and its associations with alexithymia – an fmri study in major depressive disorder and non-psychiatric controls

82 pattern separation: a potential marker of impaired hippocampal adult neurogenesis in major depressive disorder

83 formulating a return-to-work decision for employees with major depressive disorders: occupational therapists’ experiences

84 desvenlafaxine in the treatment of major depressive disorder

85 depression reduces accuracy while parkinsonism slows response time for processing positive feedback in patients with parkinson’s disease with comorbid major depressive disorder tested on a probabilistic category-learning task

86 preventive effect of liothyronine on electroconvulsive therapy-induced memory deficit in patients with major depressive disorder: a double-blind controlled clinical trial

87 effect of an educational booklet on knowledge and attitude regarding major depressive disorder in medical students in delhi

88 abnormal white matter integrity in chinese young adults with first-episode medication-free anxious depression: a possible neurological biomarker of subtype major depressive disorder

89 reduced fractional anisotropy in patients with major depressive disorder and associations with vascular stiffness

90 Meta-analysis of Plasma Interleukine-6 Levels in Patients with Depressive Disorder

91 Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset

92 Duloxetine Efficacy for Major Depressive Disorder in Male vs. Female Patients: Data From 7 Randomized, Double-Blind, Placebo-Controlled Trials

93 Quality of life and subjective sleep-related measures in bipolar disorder and major depressive disorder.

94 Major Depressive Disorder Predicts Completion, Adherence, and Outcomes in Cardiac Rehabilitation: A Prospective Cohort Study of 195 Patients With Coronary Artery Disease

95 Prediction of Probable Major Depressive Disorder in the Taiwan Biobank: An Integrated Machine Learning and Genome-Wide Analysis Approach

96 An 8-Week, Open-Label Trial of Duloxetine for Comorbid Major Depressive Disorder and Chronic Headache

97 A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of S-Adenosyl-l-Methionine (SAMe) Versus Escitalopram in Major Depressive Disorder

98 Long-Term Outcome of Major Depressive Disorder in Psychiatric Patients Is Variable

99 Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis

100 Depressive disorders among children in the transforming China: an epidemiological survey of prevalence, correlates, and service use.

101 Plasma alpha-trypsin inhibitor heavy chain 4 as an age-specific biomarker in the diagnosis and treatment of major depressive disorder.

Keyword Connections

Journals

Research Groups

Bibliographies